Calamos Wealth Management LLC Buys Shares of 30,171 Integra LifeSciences Holdings Corporation $IART

Calamos Wealth Management LLC bought a new stake in Integra LifeSciences Holdings Corporation (NASDAQ:IART) during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 30,171 shares of the life sciences company’s stock, valued at approximately $284,000.

Several other large investors have also modified their holdings of the stock. Osaic Holdings Inc. lifted its holdings in shares of Integra LifeSciences by 36.6% during the second quarter. Osaic Holdings Inc. now owns 4,119 shares of the life sciences company’s stock worth $51,000 after purchasing an additional 1,104 shares during the period. State of Tennessee Department of Treasury increased its stake in Integra LifeSciences by 7.9% in the 4th quarter. State of Tennessee Department of Treasury now owns 26,745 shares of the life sciences company’s stock valued at $332,000 after buying an additional 1,964 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in Integra LifeSciences by 5.1% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 40,441 shares of the life sciences company’s stock worth $889,000 after buying an additional 1,975 shares during the last quarter. Capital Fund Management S.A. raised its position in Integra LifeSciences by 5.7% during the 3rd quarter. Capital Fund Management S.A. now owns 37,322 shares of the life sciences company’s stock worth $535,000 after buying an additional 1,997 shares during the last quarter. Finally, Global Retirement Partners LLC acquired a new stake in shares of Integra LifeSciences in the 4th quarter worth $25,000. Hedge funds and other institutional investors own 84.78% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages have recently weighed in on IART. Truist Financial lowered their target price on shares of Integra LifeSciences from $13.00 to $12.00 and set a “hold” rating on the stock in a report on Wednesday, April 15th. Citigroup restated a “neutral” rating and issued a $19.00 price objective (up from $16.00) on shares of Integra LifeSciences in a research report on Wednesday, July 8th. Wells Fargo & Company lifted their price objective on Integra LifeSciences from $12.00 to $15.00 and gave the company an “equal weight” rating in a report on Wednesday, May 6th. Wall Street Zen upgraded Integra LifeSciences from a “buy” rating to a “strong-buy” rating in a research report on Saturday, June 13th. Finally, Argus raised Integra LifeSciences from a “hold” rating to a “buy” rating and set a $25.00 target price for the company in a research note on Thursday, June 18th. One analyst has rated the stock with a Buy rating, four have given a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat.com, Integra LifeSciences currently has an average rating of “Reduce” and an average target price of $17.17.

Integra LifeSciences Stock Up 2.1%

IART opened at $18.78 on Thursday. The company has a debt-to-equity ratio of 1.75, a quick ratio of 1.95 and a current ratio of 3.38. The company has a market cap of $1.46 billion, a price-to-earnings ratio of -2.91, a PEG ratio of 1.27 and a beta of 1.22. Integra LifeSciences Holdings Corporation has a one year low of $8.70 and a one year high of $19.13. The business’s fifty day moving average is $16.68 and its two-hundred day moving average is $12.98.

Integra LifeSciences (NASDAQ:IART) last announced its quarterly earnings results on Tuesday, May 5th. The life sciences company reported $0.54 earnings per share for the quarter, beating analysts’ consensus estimates of $0.41 by $0.13. The business had revenue of $391.92 million during the quarter, compared to analysts’ expectations of $381.81 million. Integra LifeSciences had a positive return on equity of 17.42% and a negative net margin of 30.15%.During the same quarter last year, the business posted $0.41 earnings per share. The business’s revenue for the quarter was up 2.4% on a year-over-year basis. Integra LifeSciences has set its FY 2026 guidance at 2.400-2.500 EPS and its Q2 2026 guidance at 0.440-0.520 EPS. Analysts anticipate that Integra LifeSciences Holdings Corporation will post 2.45 EPS for the current fiscal year.

Integra LifeSciences Company Profile

Integra LifeSciences Corporation is a global medical technology company specializing in products and innovations for neurosurgery, regenerative medicine and reconstructive procedures. The company develops and markets surgical instruments, implants and advanced wound care solutions designed to support tissue repair and functional recovery. Its product portfolio includes collagen-based matrices, dural substitutes, hemostatic agents and specialized spinal and peripheral fixation devices.

Founded in 1989 and headquartered in Plainsboro, New Jersey, Integra has expanded its capabilities through targeted acquisitions and internal research efforts.